ZyVersa Therapeutics, Inc.

As of March 4, 2024, ZyVersa Therapeutics, Inc. shows a mildly bearish trend with mixed signals, as daily moving averages indicate bearishness while weekly indicators are mildly bullish, suggesting a cautious short-term outlook.

ZyVersa Therapeutics, Inc. is a micro-cap company in the finance industry, currently reporting a net profit loss of $2 million and a market cap of $3.06 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -61.06%.

As of Jun 18, ZyVersa Therapeutics, Inc. has a market capitalization of 3.06 million and reported net sales of 0.00 million with a net profit of -8.84 million over the last four quarters. Shareholder's funds are 8.52 million, and total assets amount to 20.60 million.